Xiaoyu An

xiamen university

H指数:12

被引数:452

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunogen-sponge hydrogel reverses TIM-3-mediated dendritic cell dysfunction in alveolar echinococcosis

免疫原海绵水凝胶逆转肺泡棘球蚴病中TIM-3介导的树突状细胞功能障碍

Cell Reports Medicine

IF10.6

2026-11-050

COACH-D 2.0: A Server for Template-based Modeling of Protein−ligand Interactions

COACH-D 2.0：一个基于模板建模蛋白质-配体相互作用的平台

GENOMICS PROTEOMICS & BIOINFORMATICS

IF7.9

2026-07-300

Cold atmospheric plasma–engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity

冷大气压等离子体工程化纳米疫苗通过时空序贯免疫接种重编程抗肿瘤免疫

Science Advances

IF12.5

2026-03-270

BCG emulsified in lipiodol expands tumor epitope profile to boost cancer immunotherapy

BCG乳化于碘油中可扩展肿瘤表位谱以增强癌症免疫治疗

NANO TODAY

IF10.9

2025-06-010

PRE

Epigenetically Reprogrammed Nanovesicles as Inverse Vaccines for Antigen-Specific Immune Tolerance in Autoimmune Diseases

表观遗传重编程纳米囊泡作为自身免疫性疾病中抗原特异性免疫耐受的反向疫苗

NANO LETTERS

IF9.1

2025-04-110

PRE

Advances in Novel Diagnostic Techniques for Alveolar Echinococcosis

肺泡性棘球蚴病新型诊断技术的进展

DIAGNOSTICS

IF3.3

2025-02-270

RC48-ADC alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low/null expression: A multicenter, real-world, retrospective study

RC48-ADC单药或联合免疫疗法治疗HER2低/零表达的局部晚期或转移性尿路上皮癌：一项多中心、真实世界、回顾性研究

ANNALS OF ONCOLOGY

IF65.4

2024-12-011

PRE

Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody

SCIENTIFIC REPORTS

IF3.9

2024-11-150

OAAI

Enzymes in Synergy: Bacteria Specific Molecular Probe for Locoregional Imaging of Urinary Tract Infection in vivo

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

IF16.9

2024-07-181

PRE

Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models

SCIENTIFIC REPORTS

IF3.9

2024-04-192

OAAI

A Bioengineered Nanovesicle Vaccine Boosts T-B cell Interaction for Immunotherapy of Echinococcus multilocularis

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

IF16.9

2024-02-203

PRE

Designing nanodiscs as versatile platforms for on-demand therapy

NANOSCALE

IF5.1

2024-01-014

PRE

Cellular-Membrane-Derived Vesicles for Cancer Immunotherapy

PHARMACEUTICS

IF5.5

2023-12-227

OAAI

HX009, a first-inclass PD1xCD47 BsAb, demonstrated anti-AML activity in PDX models

CANCER RESEARCH

IF16.6

2023-04-041

PRE

PD-1/PD-L1 signalling axis, a double-edged sword in DSS induced colitis mouse model

CANCER RESEARCH

IF16.6

2023-04-040

PRE

HX301 (ON1232580) a novel kinase inhibitor with potent activity against CSF1R and FLT3, shows strong anti-AML activity in defined preclinical models

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Oxazolone induced atopic dermatitis mouse model using hIL-4/hIL-4Ra double knock-in mice, a preclinical mouse model for evaluating Dupilumab biosimilars

CANCER RESEARCH

IF16.6

2023-04-040

PRE

HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models

SCIENTIFIC REPORTS

IF3.9

2023-04-0312

OAAI

NGS-BASED IMMUNOLOGY PANEL: APPLICATIONS IN PRECLINICAL IMMUNO-ONCOLOGY RESEARCH

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2022-11-070

Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment

SCIENTIFIC REPORTS

IF3.9

2022-02-2843

OAAI

Xiaoyu An

个人简介

教育背景

工作经历

荣誉奖项

研究方向